{"nctId":"NCT01890421","briefTitle":"Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)","startDateStruct":{"date":"2013-07-19","type":"ACTUAL"},"conditions":["Coronary Artery Disease"],"count":426,"armGroups":[{"label":"Gadobutrol 0.1 mmol/kg body weight","type":"EXPERIMENTAL","interventionNames":["Drug: Gadobutrol (Gadovist, Gadavist, BAY86-4875)"]}],"interventions":[{"name":"Gadobutrol (Gadovist, Gadavist, BAY86-4875)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female participants aged â‰¥18 years\n* Participants with suspected or known CAD based on signs and/or (typical or atypical) chest pain who have routine CA without intervention or CTA within 4 weeks around gadobutrol-enhanced CMRI\n* Willingness to undergo stress/rest CMRI and to follow directions and complete all study procedures\n* Women of childbearing potential (e.g. age \\< 60y, no history of surgical sterilization or hysterectomy): use of contraception and a negative pregnancy test\n\nExclusion Criteria:\n\n* Suspected clinical instability or unpredictability of the clinical course during the study period\n* Contraindication to the cardiac MRI examination (e.g. inability to hold breath; severe claustrophobia, metallic devices such as pace makers)\n* History of severe allergic or anaphylactoid reaction to any allergen including drugs and contrast agents according to the investigator's assessment / judgment\n* Estimated glomerular filtration rate (eGFR) value \\<30 mL/min/1.73 m\\^2 derived from a serum / blood creatinine result within 2 weeks prior to gadobutrol injection. Any participant on hemodialysis or peritoneal dialysis is excluded from enrollment.\n* Acute renal insufficiency\n* Coronary artery bypass grafting (CABG)\n* Acute myocardial infarction (\\< 14 days prior to inclusion), unstable angina / acute coronary syndrome, severe congestive heart failure\n* Irregular heart rhythm\n* Condition that precludes the safe administration of pharmacological stressor according to the respective approved label such as sinus node disease, 2nd or 3rd degree atrioventricular block, obstructive lung disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI (Based on RPS) - Primary Analysis of Sensitivity Based on Blinded Readers' Assessment","description":"Blinded readers evaluated 6 myocardial regions based on regional perfusion score (RPS), 0=normal; 1=abnormal, reversible perfusion defect (stress); 2=abnormal, mixed perfusion defect (reversible and fixed/permanent components); 3=abnormal, fixed/permanent perfusion defect/scar (stress and rest)\\]. A myocardial region a perfusion defect in case of a RPS of \\>=1 and was rated to have normal perfusion in case of a RPS of 0. Significant CAD was defined as quantitative coronary angiography (QCA) stenosis of \\>=50% for primary analysis, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced cardiac magnetic resonance imaging (CMRI) verified by standard of reference (SoR). Sensitivity= true positive/ (true positive + false negative).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI (Based on RPS) - Additional Secondary Analysis of Sensitivity Based on the Blinded Readers' Assessment","description":"Blinded readers evaluated 6 myocardial regions based on regional perfusion score (RPS), 0=normal; 1=abnormal, reversible perfusion defect (stress); 2=abnormal, mixed perfusion defect (reversible and fixed/permanent components); 3=abnormal, fixed/permanent perfusion defect/scar (stress and rest)\\]. A myocardial region a perfusion defect in case of a RPS of \\>=1 and was rated to have normal perfusion in case of a RPS of 0. Significant CAD was defined as quantitative coronary angiography (QCA) stenosis of \\>=70% for secondary analysis, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced cardiac magnetic resonance imaging (CMRI) verified by standard of reference (SoR). Sensitivity= true positive/ (true positive + false negative). This additional secondary analysis of sensitivity was prospective analysis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI (Based on RPS) - Primary Analysis of Specificity Based on the Blinded Readers' Assessment","description":"Blinded readers evaluated 6 myocardial regions based on regional perfusion score (RPS), 0=normal; 1=abnormal, reversible perfusion defect (stress); 2=abnormal, mixed perfusion defect (reversible and fixed/permanent components); 3=abnormal, fixed/permanent perfusion defect/scar (stress and rest)\\]. A myocardial region a perfusion defect in case of a RPS of \\>=1 and was rated to have normal perfusion in case of a RPS of 0. Significant CAD was defined as quantitative coronary angiography (QCA) stenosis of \\>=50% for primary analysis, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced cardiac magnetic resonance imaging (CMRI) verified by standard of reference (SoR). Specificity= true negative/ (true negative + false positive).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI (Based on RPS) - Additional Secondary Analysis of Specificity Based on the Blinded Readers' Assessment","description":"Blinded readers evaluated 6 myocardial regions based on regional perfusion score (RPS), 0=normal; 1=abnormal, reversible perfusion defect (stress); 2=abnormal, mixed perfusion defect (reversible and fixed/permanent components); 3=abnormal, fixed/permanent perfusion defect/scar (stress and rest)\\]. A myocardial region a perfusion defect in case of a RPS of \\>=1 and was rated to have normal perfusion in case of a RPS of 0. Significant CAD was defined as quantitative coronary angiography (QCA) stenosis of \\>=70% for primary analysis, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced cardiac magnetic resonance imaging (CMRI) verified by standard of reference (SoR). Specificity= true negative/ (true negative + false positive). This additional secondary analysis of specificity was prospective analysis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Primary Analysis of Sensitivity Comparison Based on the Blinded Readers' Assessment","description":"Presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI versus the presence of wall motion abnormalities on unenhanced CMRI images (based on regional perfusion/regional wall motion score of the 6 myocardial regions) was calculated by blinded readers' assessment. Significant CAD was defined as quantitative coronary angiography (QCA) stenosis of \\>=50% for primary analysis, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced cardiac magnetic resonance imaging (CMRI) verified by standard of reference (SoR). Sensitivity= true positive/ (true positive + false negative).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Additional Secondary Analysis of Sensitivity Comparison Based on the Blinded Readers' Assessment","description":"Presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI versus the presence of wall motion abnormalities on unenhanced CMRI images (based on regional perfusion/regional wall motion score of the 6 myocardial regions) was calculated by blinded readers' assessment. Significant CAD was defined as quantitative coronary angiography (QCA) stenosis of \\>=70% for primary analysis, and was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced cardiac magnetic resonance imaging (CMRI) verified by standard of reference (SoR). Sensitivity= true positive/ (true positive + false negative). This additional secondary analysis of sensitivity was prospective analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Secondary Analysis of Sensitivity Based on Investigator's Assessment","description":"Presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI versus the presence of wall motion abnormalities on unenhanced CMRI images (based on regional perfusion/regional wall motion score of the 6 myocardial regions) was calculated by investigator's assessment. Significant CAD was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI or the presence of wall motion abnormalities on unenhanced CMRI images verified by SoR (significant CAD defined as QCA stenosis of \\>=50%). Sensitivity= true positive/ (true positive + false negative).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Sensitivity Comparison Based on Investigator's Assessment","description":"Presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI versus the presence of wall motion abnormalities on unenhanced CMRI images (based on regional perfusion/regional wall motion score of the 6 myocardial regions) was calculated by investigator's assessment. Significant CAD was determined based on the presence of a myocardial perfusion defect on gadobutrol-enhanced CMRI or the presence of wall motion abnormalities on unenhanced CMRI images verified by SoR (significant CAD defined as QCA stenosis of \\>=70%). Sensitivity= true positive/ (true positive + false negative). This additional secondary analysis of sensitivity was prospective analysis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Secondary Analysis of Specificity Based on Investigator's Assessment","description":"Investigator's assessment evaluated 6 myocardial regions based on regional perfusion score (RPS), 0=normal; 1=abnormal, reversible perfusion defect (stress); 2=abnormal, mixed perfusion defect (reversible and fixed/permanent components); 3=abnormal, fixed/permanent perfusion defect/scar (stress and rest). A myocardial region was rated to have a perfusion defect in case of a RPS of \\>=1 and was rated to have normal perfusion in case of a RPS of 0. The investigator's assessment of participant-based specificity of gadobutrol-enhanced CMRI was analyzed with significant CAD defined as maximum stenosis severity of \\>=50% by QCA, which were secondary analysis. Specificity= true negative/ (true negative + false positive).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Specificity Based on Investigator's Assessment","description":"Investigator's assessment evaluated 6 myocardial regions based on regional perfusion score (RPS), 0=normal; 1=abnormal, reversible perfusion defect (stress); 2=abnormal, mixed perfusion defect (reversible and fixed/permanent components); 3=abnormal, fixed/permanent perfusion defect/scar (stress and rest). A myocardial region was rated to have a perfusion defect in case of a RPS of \\>=1 and was rated to have normal perfusion in case of a RPS of 0. The investigator's assessment of participant-based specificity of gadobutrol-enhanced CMRI was analyzed with significant CAD defined as maximum stenosis severity of \\>=70% by QCA, which were secondary analysis. Specificity= true negative/ (true negative + false positive). This additional secondary analysis of specificity was prospective analysis.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Secondary Analysis of Sensitivity Comparison Based on Investigator's Assessment","description":"Investigator's assessment evaluated 6 myocardial regions based on regional perfusion score (RPS), 0=normal; 1=abnormal, reversible perfusion defect (stress); 2=abnormal, mixed perfusion defect (reversible and fixed/permanent components); 3=abnormal, fixed/permanent perfusion defect/scar (stress and rest). A myocardial region was rated to have a perfusion defect in case of a RPS of \\>=1 and was rated to have normal perfusion in case of a RPS of 0. The investigator's assessment of participant-based sensitivity and specificity of gadobutrol-enhanced CMRI was analyzed with significant CAD defined as maximum stenosis severity of \\>=50% by QCA, which were secondary analysis. Sensitivity= true positive/ (true positive + false negative).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Additional Secondary Analysis of Sensitivity Comparison Based on Investigator's Assessment","description":"Investigator's assessment evaluated 6 myocardial regions based on regional perfusion score (RPS), 0=normal; 1=abnormal, reversible perfusion defect (stress); 2=abnormal, mixed perfusion defect (reversible and fixed/permanent components); 3=abnormal, fixed/permanent perfusion defect/scar (stress and rest). A myocardial region was rated to have a perfusion defect in case of a RPS of \\>=1 and was rated to have normal perfusion in case of a RPS of 0. The investigator's assessment of participant-based sensitivity and specificity of gadobutrol-enhanced CMRI was analyzed with significant CAD defined as maximum stenosis severity of \\>=70% by QCA, which were secondary analysis. Sensitivity= true positive/ (true positive + false negative). This additional secondary analysis of sensitivity was prospective analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Localization of a Myocardial Perfusion Defect to a Coronary Territory on Gadobutrol-Enhanced CMRI - Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessments","description":"Sensitivity was calculated coronary territory based, a coronary territory (left anterior descending artery \\[LAD\\] / non-LAD / right coronary artery \\[RCA\\] / left circumflex artery \\[LCX\\]) was rated positive for significant CAD (significant CAD defined as QCA stenosis of\\>=50%), if \\>=1 myocardial region within the same coronary territory showed a myocardial perfusion defect with a RPS of \\>=1. A coronary territory(LAD / non-LAD) was rated negative for significant CAD, if no myocardial region within the respective coronary territory showed a myocardial perfusion defect (RPS 0). Sensitivity was displayed for all 3 blinded readers and the investigator.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Localization of a Myocardial Perfusion Defect to a Coronary Territory on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessments","description":"Sensitivity was calculated coronary territory based, a coronary territory (LAD / non-LAD / RCA / LCX) was rated positive for significant CAD (significant CAD defined as QCA stenosis of \\>=70%), if \\>=1 myocardial region within the same coronary territory showed a myocardial perfusion defect with a RPS of \\>=1. A coronary territory (LAD / non-LAD) was rated negative for significant CAD, if no myocardial region within the respective coronary territory showed a myocardial perfusion defect (RPS 0). Sensitivity was displayed for all 3 blinded readers and the investigator. This additional secondary analysis of sensitivity was prospective analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Localization of a Myocardial Perfusion Defect to a Coronary Territory on Gadobutrol-enhanced CMRI - Secondary Analysis of Specificity Based on Blinded Readers' and Investigator's Assessments","description":"Specificity was calculated coronary territory based, a coronary territory (LAD / non-LAD / RCA / LCX) was rated positive for significant CAD (significant CAD defined as QCA stenosis of \\>=50%), if \\>=1 myocardial region within the same coronary territory showed a myocardial perfusion defect with a RPS of \\>=1. A coronary territory (LAD / non-LAD) was rated negative for significant CAD, if no myocardial region within the respective coronary territory showed a myocardial perfusion defect (RPS 0). Specificity was displayed for all 3 blinded readers and the investigator.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Localization of a Myocardial Perfusion Defect to a Coronary Territory on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Specificity Based on Blinded Readers' and Investigator's Assessments","description":"Specificity was calculated coronary territory based, a coronary territory (LAD / non-LAD / RCA / LCX) was rated positive for significant CAD (significant CAD defined as QCA stenosis of \\>=70%), if \\>=1 myocardial region within the same coronary territory showed a myocardial perfusion defect with a RPS of \\>=1. A coronary territory (LAD / non-LAD) was rated negative for significant CAD, if no myocardial region within the respective coronary territory showed a myocardial perfusion defect (RPS 0). Specificity was displayed for all 3 blinded readers and the investigator. This additional secondary analysis of specificity was prospective analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Detection of Myocardial Perfusion Defect(s) on Gadobutrol-enhanced CMRI in Participants With Significant LMS Stenosis - Based on Blinded Readers' and Investigator's Assessments","description":"Sensitivity was calculated for detection of myocardial perfusion defects on gadobutrol-enhanced CMRI in participants with significant left main stem (LMS) stenosis and the myocardial perfusion defect pattern was described. If \\>=1 myocardial region showed a myocardial perfusion defect with a RPS of \\>=1, participants will be rated positive for significant CAD (significant CAD defined as QCA stenosis of \\>=50%). Sensitivity= true positive/ (true positive + false negative).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence/Absence of a MPD Indicating/Excluding Significant CAD in Participants With Multi Versus Single Vessel Disease Evaluated on Gadobutrol-enhanced CMRI-Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessments","description":"Sensitivity was calculated for detection of myocardial perfusion defects (MPD) on gadobutrol-enhanced CMRI in participants with single and multi-vessel diseases. If \\>=1 myocardial region showed a myocardial perfusion defect with a RPS of \\>=1, participants will be rated positive for significant CAD (significant CAD defined as QCA stenosis of \\>=50%). Sensitivity= true positive/ (true positive + false negative).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence/Absence of a MPD Indicating/Excluding Significant CAD in Participants With Multi Vs Single Vessel Disease Evaluated on Gadobutrol-enhanced CMRI-Additional Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessments","description":"Sensitivity was calculated for detection of MPD on gadobutrol-enhanced CMRI in participants with single and multi-vessel diseases. If \\>=1 myocardial region showed a myocardial perfusion defect with a RPS of \\>=1, participants will be rated positive for significant CAD (significant CAD defined as QCA stenosis of \\>=70%). Sensitivity= true positive/ (true positive + false negative). This additional secondary analysis of sensitivity was prospective analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants by Their Lowest Confidence in Diagnosis Obtained on Gadobutrol-enhanced CMRI and Unenhanced Wall Motion CMRI - Based on Blinded Readers' and Investigator's Assessments","description":"Score for confidence in diagnosis (not confident, somewhat confident, and confident) was described descriptively for each of the 6 myocardial regions. The frequency over the worst confidence in diagnosis obtained within a participant was displayed. All these analyses were done separately for gadobutrol-enhanced CMRI and unenhanced wall motion CMRI.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":426},"commonTop":["Chest discomfort","Headache","Angina pectoris","Feeling hot","Dyspnoea"]}}}